News headlines about Biodel (NASDAQ:ALBO) have been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Biodel earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.1846035652854 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Biodel (NASDAQ ALBO) traded up 12.55% during mid-day trading on Friday, reaching $27.00. 16,966 shares of the company were exchanged. Biodel has a 12-month low of $14.00 and a 12-month high of $37.69. The company’s 50 day moving average price is $22.89 and its 200-day moving average price is $22.26. The stock’s market capitalization is $239.81 million.
Biodel (NASDAQ:ALBO) last announced its quarterly earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). On average, equities research analysts forecast that Biodel will post ($3.64) earnings per share for the current fiscal year.
A number of analysts recently weighed in on the stock. ValuEngine cut shares of Biodel from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Wedbush reissued an “outperform” rating and issued a $58.00 target price on shares of Biodel in a research note on Monday, September 11th. Zacks Investment Research raised shares of Biodel from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Tuesday, July 11th. Needham & Company LLC assumed coverage on shares of Biodel in a research note on Tuesday, July 18th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Cowen and Company assumed coverage on shares of Biodel in a research note on Wednesday, August 16th. They issued an “outperform” rating on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. Biodel has a consensus rating of “Buy” and an average target price of $40.33.
COPYRIGHT VIOLATION WARNING: This article was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.themarketsdaily.com/2017/10/13/biodel-albo-earns-daily-coverage-optimism-rating-of-0-04.html.
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.